Pink Eye (Conjunctivitis)



Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis


Conditions:   Conjunctivitis, Allergic;   Conjunctivitis, Vernal
Interventions:   Drug: Hyaluronic acid 0.05% & Ectoine 2.0%;   Drug: Olopatadine hydrochloride ophthalmic solution 0.1%
Sponsors:   Michael Marchand, MD;   Université de Montréal
Recruiting


ADenoVirus Initiative Study in Epidemiology in Italy


Condition:   Viral Conjunctivitis
Intervention:  
Sponsor:   NicOx
Completed


A Study of ADX-102 in Subjects With Allergic Conjunctivitis


Condition:   Conjunctivitis, Allergic
Interventions:   Drug: ADX-102 Ophthalmic Drops (0.5%);   Drug: ADX-102 Ophthalmic Drops (0.1%);   Drug: Vehicle of ADX-102 Ophthalmic Drops
Sponsors:   Aldeyra Therapeutics, Inc.;   ORA, Inc.
Completed


Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo


Condition:   Bacterial Conjunctivitis
Interventions:   Drug: SHP640;   Drug: PVP-I 0.6%;   Drug: Placebo
Sponsor:   Shire
Recruiting


Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo


Condition:   Adenoviral Conjunctivitis
Interventions:   Drug: SHP640;   Drug: Placebo
Sponsor:   Shire
Recruiting


Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo


Condition:   Adenoviral Conjunctivitis
Interventions:   Drug: SHP640;   Drug: PVP-I 0.6%;   Drug: Placebo
Sponsor:   Shire
Recruiting


Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®)


Condition:   Chronic Allergic Conjunctivitis
Interventions:   Drug: OTX-DP (Dexamethasone);   Other: Placebo - PV
Sponsors:   Ocular Therapeutix, Inc.;   ORA, Inc.
Completed


Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)


Condition:   Bacterial Conjunctivitis
Interventions:   Drug: PRO-157;   Drug: Vigamox;   Drug: Zymar®;   Drug: Lagricel Ofteno®
Sponsor:   Laboratorios Sophia S.A de C.V.
Completed


Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Biological: ST266;   Drug: Saline (0.9% NaCl)
Sponsor:   Noveome Biotherapeutics, formerly Stemnion
Active, not recruiting


Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea


Condition:   Conjunctivitis, Allergic
Intervention:   Drug: Alcaftadine Ophthalmic Solution 0.25%
Sponsor:   Allergan
Recruiting


Perforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients


Conditions:   Epiphora;   Conjunctivitis
Interventions:   Device: Perforated Punctal plugs;   Procedure: Crawford tube insertion;   Device: Crawford lacrimal tube
Sponsors:   Rabin Medical Center;   Alpha Net Co. Ltd.
Completed


Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Drug: OTX-DP treatment;   Device: Placebo Plug with no drug
Sponsors:   Ocular Therapeutix, Inc.;   ORA, Inc.
Completed


Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis


Condition:   Bacterial Conjunctivitis
Interventions:   Drug: Vancomycin 1.1%;   Drug: Placebo
Sponsor:   Kurobe LLC
Recruiting


Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects


Condition:   Allergic Conjunctivitis
Interventions:   Drug: Olopatadine Hydrochloride Ophthalmic Solution 0.2%;   Drug: Olopatadine Hydrochloride Ophthalmic Solution 0.1%;   Drug: Olopatadine 0.2% Vehicle
Sponsor:   Alcon Research
Completed


ADenoVirus Initiative Study in Epidemiology in Spain


Condition:   Viral Conjunctivitis
Intervention:  
Sponsor:   NicOx
Completed


Phase 2/3 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Drug: OTX-DP treatment;   Device: Placebo Plug with no drug
Sponsors:   Ocular Therapeutix, Inc.;   ORA, Inc.
Completed


ADenoVirus Initiative Study in Epidemiology in France


Condition:   Viral Conjunctivitis
Intervention:  
Sponsor:   NicOx
Completed


ADenoVirus Initiative Study in Epidemiology in Germany


Condition:   Viral Conjunctivitis
Intervention:  
Sponsor:   NicOx
Completed


Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Drug: hydrocortisone ophthalmic ointment 0.5%;   Drug: placebo
Sponsors:   Koffler Vision Group;   Fera Pharmaceuticals, LLC
Terminated


Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Drug: bepotastine besilate, 1.5%;   Drug: Loteprednol etabonate
Sponsor:   Southern California College of Optometry
Completed


Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model


Condition:   Allergic Conjunctivitis
Interventions:   Drug: AC-170 0.05%;   Drug: AC-170 0.1%;   Drug: AC-170 0.24%;   Drug: AC-170 0%
Sponsor:   Aciex Therapeutics, Inc.
Completed


Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model


Condition:   Allergic Conjunctivitis
Interventions:   Drug: AC-150 Combo;   Drug: AC-150A 0.1%;   Drug: AC-150B 0.005%;   Drug: Vehicle
Sponsor:   Aciex Therapeutics, Inc.
Completed


Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Drug: Lifitegrast;   Other: Placebo
Sponsor:   Shire
Completed


AL-15469A for the Treatment of Bacterial Conjunctivitis


Condition:   Bacterial Conjunctivitis
Interventions:   Drug: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%;   Drug: Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Sponsor:   Alcon Research
Completed


Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis


Condition:   Allergic Conjunctivitis
Interventions:   Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%;   Drug: Olopatadine Hydrochloride Ophthalmic Solution Vehicle
Sponsor:   Alcon Research
Completed

Refine Your Search Advanced Search